洛伐他汀对产蛋鸡胆固醇代谢的调节机理研究

Mechanism of Lovastatin Regulating Cholesterin Metabolism in Laying Hens

本试验旨在考察洛伐他汀的降胆固醇作用是否由一磷酸腺苷激活的蛋白激酶(AMPK)所介导。选用健康的产蛋率、体重相近的47周龄新罗曼蛋鸡20只,分为2个处理,每个处理5个重复,每个重复2只鸡,单笼饲养,分别饲喂基础日粮(对照组)和试验日粮(基础日粮中添加0.06%洛伐他汀),正式试验期为3周。结果表明:1)添加0.06%洛伐他汀不影响产蛋鸡生产性能,并可以降低鸡蛋胆固醇含量。与对照组相比,按每克蛋黄胆固醇含量(mg/g蛋黄)计,第1、2、3周分别降低11.56%、10.88%和12.75%(P<0.05);按全蛋总胆固醇(mg/个蛋黄)计,第1、2、3周分别降低16.01%、17.95%和19.79%(P<0.05);2)添加0.06%洛伐他汀,使产蛋鸡肝脏AMPK活性提高5.69%(P>0.05),β-羟基-β-甲基戊二酸单酰辅酶A还原酶(HMGR)、乙酰辅酶A羧化酶(ACC)活性分别降低21.89%(P<0.05)和9.72%(P>0.05);3)细胞培养液中加入0.3 mmol/L洛伐他汀,产蛋鸡肝细胞AMPK活性提高5.02%(P>0.05),同时加入0.3 mmol/L洛伐他汀和0.5 mmol/L Br^8-AMP(AMPK的抑制剂)时,AMPK活性较洛伐他汀组降低4.57%(P>0.05)。由此可知,洛伐他汀的降胆固醇作用可能部分由AMPK介导。

The trial was conducted to study whether adenosine monophosphate protein kinase （AMPK） could regulate the cholesterin reduction effect of lovastatin which was metabolic product of cholesterin in laying hens. Twenty 47-week-old new Roman laying hens were allotted to two groups with five replicates in each group and two hens in each replicate. Laying hens were fed the basal diet （control group） and the trial diet which added 0.06% lovastatin in the basal diet, respectively. The trial lasted for 3 weeks. The results showed that： 1） 0.06% lovastatin could maintain performance of laying hens and reduce the cholesterin content of eggs. Compared with control group, the cholesterin content of egg yolk （mg/g egg yolk） reduced 11.56%, 10.88% and 12.75% in the first, second and third week, respectively （P〈0.05） ; and the cholesterin content of whole egg yolk （mg/yolk） reduced 16.01%, 17.95% and 19.79% （P〈0.05） in the first, second and third week, respectively; 2） 0.06% lovastatin could increase the activity of AMPK by 5.69% （P〉0.05） and reduce the activities of β-hydrox- y-β-methylglutary-CoA reductas （HMGR） and acetyl-CoA carboxylase （ACC） by 21.89% （P〈0.05） and 9.72% （P 〉0.05） in the liver of laying hens, respectively; 3） cell culture fluid added with 0.3 mmol/L lovastatin could enhance the activity of AMPK by 5.02% in liver cells of laying hens （P〉0.05） ; compared with which added with 0.3 mmol/L lovastatin, cell culture fluid added with both 0.3 mmol/L lovastatin and 0.5 mmol/L BrS-AMP （AMPK inhibitor） could reduce the activity of AMPK by 4.57% （P〉0.05）. It was concluded that the cholesterin reduction effect of lovastatin may be mediated by AMPK partly.